Pacific Biosciences of California, Inc. - Common Stock (NQ:PACB)

2.250 +0.140 (+6.64%)

Delayed Quote Updated: 4:00 PM EDT, Oct 26, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Pacific Biosciences of California, Inc. - Common Stock

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

Why Is Pacific Biosciences (PACB) Stock Up 5% Today? ↗

August 11, 2022

Shareholders in Pacific Biosciences and PACB stock certainly have a lot to cheer today, as investors go wild for biotech companies.

Via InvestorPlace

Why Matterport Is Trading Higher By Around 25%, Here Are 73 Stocks Moving In Thursday's Mid-Day Session ↗

August 11, 2022

Gainers Timber Pharmaceuticals, Inc. (NYSE: TMBR) shares rose 63.8% to $0.1769. Timber Pharmaceuticals recently announced closing of $8.0 million public offering.

Via Benzinga

Pacific Biosciences Clocks 14% Jump In Q1 Revenues ↗

May 05, 2022

Via Benzinga

Pacific Biosciences Shares Fall As Q4 Earnings Miss Estimates ↗

February 16, 2022

Pacific Biosciences of California Inc (NASDAQ: PACB) reported

Via Benzinga

Stocks That Hit 52-Week Lows On Tuesday ↗

January 18, 2022

Tuesday morning saw 454 companies set new 52-week lows. Interesting Facts About Today's 52-Week Lows: Unilever (NYSE:UL) was the largest firm by market cap to set a...

Via Benzinga

Disney, Inotiv, Warby Parker And Some Other Big Stocks Moving Higher On Thursday ↗

August 11, 2022

Absci Corporation (NASDAQ: ABSI) jumped 38.8% to $5.83 after the company reported a narrower Q2 loss.

Via Benzinga

5 Top Stocks Cathie Wood Bought This Week ↗

August 05, 2022

Cathie Wood continues to increase positions in some of her top stocks despite recession fears. She bought names like EXAS and PACB this week.

Via InvestorPlace

Cathie Wood Sheds $5M In CRISPR Therapeutics, Scoops Up These Biotech Stocks Instead ↗

August 05, 2022

Cathie Wood-led Ark Investment Management on Thursday sold 70,723 shares of gene editing company CRISPR Therapeutics AG (NASDAQ: CRSP), valued at over $5.58 million, via its flagship fund.

Via Benzinga

Small Cap Biotech Stocks Are Trending Well ↗

July 18, 2022

Despite a little weakness last week, small cap biotechs are trending well for traders. For investors entering the trade on July 5 all of our. focus stocks are up except ChemoCentryx.

Via Talk Markets

Piper Sandler Maintains Neutral Rating for Pacific Biosciences: Here's What You Need To Know ↗

May 16, 2022

Piper Sandler has decided to maintain its Neutral rating of Pacific Biosciences (NASDAQ:PACB) and lower its price target from $13.00 to $6.00. Shares of Pacific Biosciences are trading down 2.74% over...

Via Benzinga

Recap: Pacific Biosciences Q1 Earnings ↗

May 04, 2022

Pacific Biosciences (NASDAQ:PACB) reported its Q1 earnings results on Wednesday, May 4, 2022 at 04:00 PM. Here's what investors need to know about the announcement.

Via Benzinga

Lessons For Elon Musk: 5 Notorious Failed Hostile Takeovers ↗

April 16, 2022

Let’s pause to consider earlier attempts at hostile takeovers by well-respected and well-financed entities and individuals that — to ransack some Musk-worthy clichés — took off like a rocket ship but...

Via Talk Markets

Lessons For Elon Musk: 5 Notorious Failed Hostile Takeovers ↗

April 15, 2022

As any student of industry knows, Elon Musk is hardly the first person to attempt a hostile takeover.

Via Benzinga

Stocks That Hit 52-Week Lows On Thursday ↗

April 21, 2022

On Thursday, 236 companies hit new 52-week lows.

Via Benzinga

Stocks That Hit 52-Week Lows On Wednesday ↗

April 20, 2022

On Wednesday, 160 companies hit new 52-week lows. Areas of Significance In Today's 52-Week Lows: Walt Disney (NYSE:DIS) was the largest firm by market cap to set a new...

Via Benzinga

How do Biotechnology Funds and ETFs Perform Over Five Years? ↗

March 21, 2022

Biotech investing can be difficult for short-term traders but can offer good returns over five years if balanced with other healthcare positions like the XLV.

Via Talk Markets

The Daily Biotech Pulse: Avenue Tumbles On Negative Adcom Verdict, Moderna's Expanded Deal With Rovi, Gilead Takes Equity Stake In Hookipa ↗

February 16, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Hookipa Gets $15M Upfront Payment And Equity Investment From Gilead Following...

Via Benzinga

23 Stocks Moving in Wednesday's Pre-Market Session ↗

February 16, 2022

Gainers HOOKIPA Pharma Inc. (NASDAQ: HOOK) rose 41.8% to $1.90 in pre-market trading after the company announced it entered into an amended and restated collaboration...

Via Benzinga

Stocks That Hit 52-Week Lows On Tuesday ↗

March 15, 2022

During Tuesday's session, 454 stocks hit new 52-week lows. Intriguing Points From Today's 52-Week Lows: Taiwan Semiconductor (NYSE:TSM) was the largest company by...

Via Benzinga

Recap: Pacific Biosciences Q4 Earnings ↗

February 15, 2022

Pacific Biosciences (NASDAQ:PACB) reported its Q4 earnings results on Tuesday, February 15, 2022 at 04:00 PM. Here's what investors need to know about the announcement.

Via Benzinga

The Daily Biotech Pulse: Larimar Plunges On Extension Of Clinical Hold, ImmunityBio Gains On Positive Data, Adcom Test Awaits Avenue Therapeutics ↗

February 15, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus ImmunityBio Says Cancer Combo Therapy Produces Positive Results In Late-Stage...

Via Benzinga

The Week Ahead In Biotech (Feb. 13-19): Agios FDA Meeting, Avenue Adcom, Earnings And More ↗

February 13, 2022

Biotech stocks moved back and forth amid some volatility before finishing the week ending Feb. 11 modestly lower, reversing the gains from the previous week. Earnings news...

Via Benzinga

Earnings Scheduled For February 15, 2022 ↗

February 15, 2022

Companies Reporting Before The Bell • FirstService (NASDAQ:FSV) is estimated to report quarterly earnings at $1.31 per share on revenue of $1.07 billion.

Via Benzinga

Bionano Is Not the Genomics Stock To Bet On ↗

February 04, 2022

Bionano's recent results are lackluster and point to more volatility ahead for BNGO stock. Best to just avoid this stock for now.

Via InvestorPlace

48 Biggest Movers From Yesterday ↗

January 12, 2022

Gainers Splash Beverage Group, Inc. (NYSE: SBEV) shares jumped 70.6% to close at $1.80 on Tuesday after the company announced it received authorization to sell its TapouT...

Via Benzinga

Mid-Afternoon Market Update: Dow Rises 150 Points; Accolade Shares Spike Higher ↗

January 11, 2022

Toward the end of trading Tuesday, the Dow traded up 0.43% to 36,224.50 while the NASDAQ rose 1.33% to 15,142.08. The S&P also rose, gaining, 0.75% to 4,705.23. The U.S. has...

Via Benzinga

Stocks That Hit 52-Week Lows On Wednesday ↗

January 19, 2022

During Wednesday's morning trading, 400 companies set new 52-week lows. 52-Week Low Highlights: Intuitive Surgical (NASDAQ:ISRG) was the largest company by...

Via Benzinga

Illumina Jumps As Gene Sequencing Demand Drives Stronger Outlook ↗

January 11, 2022

Piper says Pacific Bio has a new competitor in Illumina amid plans to launch what looks like a consumable allowing long-read sequencing on its analyzers.

Via Talk Markets

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

January 11, 2022

Gainers Nutriband (NASDAQ:NTRB) stock moved upwards by 20.7% to $7.29 during Tuesday's regular session. Trading volume for Nutriband's stock is 6.4 million as of...

Via Benzinga

Mid-Day Market Update: Crude Oil Rises 3.5%; Pacific Biosciences of California Shares Fall ↗

January 11, 2022

Midway through trading Tuesday, the Dow traded down 0.50% to 35,889.26 while the NASDAQ fell 0.16% to 14,919.61. The S&P also fell, dropping, 0.39% to 4,652.01. The U.S. has...

Via Benzinga

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.